June 24, 2009 - Naviscan Inc., a molecular breast imaging (MBI) provider, has entered into a distribution agreement with Hae Dong Co. Ltd. to market and serve Naviscan’s high-resolution organ-specific PET scanner, whose breast application is known as positron emission mammography (PEM), in the Republic of South Korea.

The first unit will be installed at Seoul National University Hospital, where it will be available to physicians and researchers while awaiting Korean FDA approval.

Naviscan manufactures is a commercially available PEM imaging scanner and PEM-guided biopsy system. The scanner uses PET technology to produce tomographic images that allow physicians to visualize breast tumors down to 2 mm, the width of a grain of rice. The scanner is the size of a mammography unit and uses gentle breast immobilization, allowing for greater patient comfort, as well as reducing motion artifact and improving image resolution.

Hae Dong Co. Ltd. is the leader in the Korean market for Radiation Oncology products and Nuclear Medicine. As a distributor of Philips whole-body PET scanners, and producer and distributor of Fluorodeoxyglucose or FDG (the positron-emitting radioactive isotope used in PET), the Naviscan PEM scanner complements Hae Dong’s molecular imaging suite of solutions.

Additional distributorships have been selected in Mexico, Venezuela and Colombia. Naviscan will be launching in those countries by the fourth quarter of 2009.

For more information: www.naviscan.com


Related Content

News | PET-MRI

June 10, 2026 — UTHealth Houston has launched a state-of-the-art PET/MRI imaging service, bringing together two advanced ...

Time June 12, 2026
arrow
News | Nuclear Imaging

June 1, 2026 — At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE HealthCare will ...

Time June 02, 2026
arrow
News | Women's Health

June 2, 2026 — Results of an American College of Radiology-managed retrospective study involving 110,000 women presented ...

Time June 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 27, 2026 — Subtle Medical has received FDA clearance for its SubtleHD (PET), the company's next-generation AI ...

Time May 27, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
News | Women's Health

April 16, 2026 – GE HealthCare has expanded its collaboration with DeepHealth, Inc., a wholly-owned subsidiary of RadNet ...

Time April 20, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
Subscribe Now